EGFR and cancer: In particular, 4 SL pairs: mTOR-TP53, VEGFR2-TP53, EGFR-TP53, ATM-PRKCA, could be validated using drug sensitivity information in the cancer cell line databases CCLE or NCI60. Furthermore, the results of siRNA knock-down experiments indicated that significant differences in the cell growth of mTOR or EGFR siRNA knock-down were detected between the cancer cells with wild type TP53 and mutant TP53.